Leflunomide: Is a new oral agent in treatment of acute pancreatitis?

Pancreas

Volumn 39, Issue 2, 2010, Pages 237-242

  Kutluana, Ufuk ^a   Oruc, Nevin ^b   Nart, Deniz ^b   Kaptanoglu, Bunyamin ^a   Yonetci, Nadir ^a   Ozutemiz, Omer ^b  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Leflunomide; Pancreatitis; Rat; Taurocholate

Indexed keywords

AMYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; MALONALDEHYDE; MYELOPEROXIDASE; NITRIC OXIDE;

ACUTE HEMORRHAGIC PANCREATITIS; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EDEMA; HISTOPATHOLOGY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; RAT; THERAPY EFFECT;

ADMINISTRATION, ORAL; AMYLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; ISOXAZOLES; MALE; MALONDIALDEHYDE; NEUTROPHIL INFILTRATION; NITRIC OXIDE; PANCREAS; PANCREATITIS, ACUTE NECROTIZING; PEROXIDASE; PULMONARY EDEMA; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; TAUROCHOLIC ACID;

EID: 77649246747     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bab6a9     Document Type: Article

References (49)

1. Banerjee AK, Steele RJ. Current views on the pathophysiology of acute biliary pancreatitis. Gut. 1995;36:803-805.
2. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2002;9:401-410.
3. Satoh A, Shimosegawa T, Fujita M, et al. Inhibition of nuclear factor-JB activation improves the survival of rats with taurocholate pancreatitis. Gut. 1999;44:253-258.
4. Algul H, Tando Y, Schneider G, et al. Acute experimental pancreatitis and NFJB/Rel activation. Pancreatology. 2002;2:503-509.
5. Frossard JL, Pastor CM, Hadengue A. Effect of hyperthermia on NF-kappaB binding activity in cerulein-induced acute pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2001;280:1157-1162.
6. Jaffray C, Yang J, Carter G, et al. Pancreatic elastase activates pulmonary nuclear factor J B and inhibitory J B, mimicking pancreatitis- associated adult respiratory distress syndrome. Surgery. 2000;128:225-231.
7. Rakonczay Z Jr, Hegyi P, Takács T, et al. The role of NF-JB activation in the pathogenesis of acute pancreatitis. Gut. 2008;57:259-267.
8. Blackwell TS, Christman JW. The role of nuclear factor J B in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997;17:3-9.
9. Long J, Song N, Liu XP, et al. Nuclear factor-JB activation on the reactive oxygen species in acute necrotizing pancreatitic rats. World J Gastroenterol. 2005;11:4277-4280.
10. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 1995;38:1595-1603.
11. Silva Júnior H, Morris RE. Leflunomide and malononitrilamides. Am J Med Sci. 1997;313:289-301.
12. Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol. 1999;127:1589-1596.
13. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-JB activation and gene expression. J Immunol. 1999;162:2095-2102.
14. Schwarz M, Thomsen J, Meyer H, et al. Frequency and time course of pancreatic and extra pancreatic bacterial infection in experimental acute pancreatitis in rats. Surgery. 2000;127:427-432.
15. Karaman A, Fadillioglu E, Turkmen E, et al. Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. Pediatr Surg Int. 2006;22:428-434.
16. Chong AS, Huang W, Liu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation. 1999;68:100-109.
17. Ozturk E, Demirbilek S, Begec Z, et al. Does leflunomide attenuate the sepsis-induced acute lung injury? Pediatr Surg Int. 2008;24: 899-905.
18. Spormann H, Sokolowski A, Letko G. Effect temporary ischemia upon development and histological patterns of acute pancreatitis in the rat. Path Res Pract. 1989;184:507-513.
19. Tran DD, Cuesta MA, Schneider AJ, et al. Prevalence and prediction of multiple organ system failure and mortality in acute pancreatitis. J Crit Care. 1993;8(3):145-153.
20. Lichtenstein A, Milani R, Fernezlian SM, et al. Acute lung injury in two experimental models of acute pancreatitis: infusion of saline or sodium taurocholate into the pancreatic duct. Crit Care Med. 2000;28(5):1497-1502.
21. Kuebler WM, Abels C, Schuerer L, et al. Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assay. Int J Microcirc Clin Exp. 1996;16:89-97.
22. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: Malonaldehyde and 4-hydroxynonenal. In: Packer L, Glazer AN, eds. Methods in Enzymology, vol 186. Oxygen Radicals in Biological Systems. New York, NY: Academic; 1990: 407-421.
23. Navarro-Gonzálvez JA, GarcNa-Benayas C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem. 1998;44:679-681.
24. Cosen-Binker LI, Binker MG, Negri G, et al. Experimental model of acute pancreatitis in Wistar rat: glucocorticoid treatment profile. Dig Dis Sci. 2003;48(8):1453-1464.
25. Chao KC, Chao KF, Chuang CC, et al. Blockade of interleukin 6 accelerates acinar cell apoptosis and attenuates experimental acute pancreatitis in vivo. Br J Surg. 2006;93(3):332-338.
26. Oruc N, Ozutemiz AO, Yukselen V, et al. Infliximab: a new therapeutic agent in acute pancreatitis? Pancreas. 2004;28(1):e1-e8.
27. Cao Y, Adhikari S, Clément MV, et al. Induction of apoptosis by crambene protects mice against acute pancreatitis via anti-inflammatory pathways. Am J Pathol. 2007;170(5):1521-1534.
28. Gukovsky I, Gukovskaya AS, Blinman TA, et al. Early NF-JB activation is associated with hormone-induced pancreatitis. Am J Physiol. 1998;275:1402-1414.
29. Vaquero E, Gukovsky I, Zaninovic V, et al. Localized pancreatic NFJB activation and inflammatory response in taurocholate-induced pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2001; 280:1197-1208.
30. Dunn JA, Li C, Ha T, et al. Therapeutic modification of nuclear factor J B binding activity and tumor necrosis factor-alpha gene expression during acute biliary pancreatitis. Am Surg. 1997;63: 1036-1043.
31. Telek G, Ducroc R, Scoazec JY, et al. Differential upregulation of cellular adhesion molecules at the sites of oxidative stress in experimental acute pancreatitis. J Surg Res. 2001;96:56-67.
32. Altavilla D, Famulari C, Passaniti M, et al. Attenuated cerulean induced pancreatitis in nuclear factor-JBYdeficient mice. Lab Invest. 2003;83: 1723-1732.
33. Ramudo L, Manso MA, Sevillano S, et al. Kinetic study of TNF > production and its regulatory mechanisms in acinar cells during acute pancreatitis induced by bile-pancreatic duct obstruction. J Pathol. 2005;206:9-16.
34. Shi C, Zhao X, Wang X, et al. Role of nuclear factor-JB, reactive oxygen species and cellular signaling in the early phase of acute pancreatitis. Scand J Gastroenterol. 2005;40:103-108.
35. Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci. 2002;323: 190-193.
36. Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2003;30:1182-1190.
37. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002;73:358-366.
38. Prajapati DN, Knox JF, Emmons J, et al. Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol. 2003;37:125-128.
39. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000;47:273-289.
40. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841-849.
41. Li WD, Ran GX, Teng HL, et al. Dynamic effects of leflunomide on IL-1, IL-6, and TNF-> activity produced from peritoneal macrophages in adjuvant arthritis rats. Acta Pharmacol Sin. 2002;23:752-756.
42. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-J B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol. 2000;165:5962-5969.
43. Imose M, Nagaki M, Kimura K, et al. Leflunomide protects from T cell mediated liver injury in mice through inhibition of nuclear factor-JB. Hepatology. 2004;40:1160-1169.
44. Bartlett RR, Anagnostopulos H, Zielinski T, et al. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol. 1993;14:381-394.
45. Reddy SV, Wanchu A, Khullar M, et al. Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis. Int Immunopharmacol. 2005;5(6):1085-1090.
46. Steinle AU, Weidenbach H, Wagner M, et al. NF-JB/Rel activation in cerulean pancreatitis. Gastroenterology. 1999;116:420-430.
47. Satoh A, Gukovskaya AS, Nieto JM, et al. PKC-C and -D regulate NFJB activation induced by cholecystokinin and TNF-> in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:582-591.
48. Gray KD, Simovic MO, Chapman WC, et al. Systemic NF-JB activation in a transgenic mouse model of acute pancreatitis. J Surg Res. 2003;110:310-314.
49. Lankisch P, Hahlf G, Koop H. Pulmonary complications in fatal haemorrhagic acute pancreatitis. Dig Dis Sci. 1983;28:111-116.